Last reviewed · How we verify

Intermittent insulin therapy

Mount Sinai Hospital, Canada · Phase 3 active Small molecule

Intermittent insulin therapy delivers insulin in periodic cycles rather than continuous infusion to improve glycemic control while potentially reducing hypoglycemia risk and insulin resistance.

Intermittent insulin therapy delivers insulin in periodic cycles rather than continuous infusion to improve glycemic control while potentially reducing hypoglycemia risk and insulin resistance. Used for Type 2 diabetes mellitus.

At a glance

Generic nameIntermittent insulin therapy
Also known asBasal insulin glargine and pre-meal insulin lispro
SponsorMount Sinai Hospital, Canada
Drug classInsulin therapy (intermittent dosing regimen)
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

This approach alternates periods of insulin administration with insulin-free intervals, theoretically allowing pancreatic beta cells to recover function and reducing the development of insulin resistance. The intermittent dosing pattern may also lower the overall insulin requirement while maintaining adequate blood glucose control in diabetic patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results